Mark D. Davis, PA-C

Mark Davis practices at Texas Oncology PA in Fort Worth, Texas.

Mark Davis' NPI, 1679580435, was assigned on August 2, 2006. Mark Davis holds Texas license PA06442.

Mark Davis' primary practice is Texas Oncology PA, at 6500 Harris Pkwy, Fort Worth, TX 76132 in Tarrant County. The practice phone is (972) 997-8000.

Mark Davis' primary practice is Texas Oncology PA in Fort Worth, Texas. Mark Davis is also affiliated with Texas Health Southwest Fort Worth. The medical group on file is University of Texas Southwestern Medical Center. Dmand AI also links Mark Davis to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Mark Davis practices, 2 sites in all. Vendor and product names are available with a free account.

Medical is Mark Davis' primary specialty in the NPI Registry, under taxonomy code 363AM0700X. Mark Davis is board certified in certified physician assistant by the National Commission on Certification of Physician Assistants (NCCPA). Dmand AI has Mark Davis' licenses on file in 2 states: Texas and Michigan.

CMS data shows 2,372 Medicare services from Mark Davis across 18 procedure codes in 2024, for 278 Medicare patients. Medicare paid $59,203 for them. Every service was in an office.

CMS counts 278 Medicare patients who saw Mark Davis in 2024. The largest group is 65 to 74, with 115 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.91, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Mark Davis' median patient age at 71, with 64% women.

In 2024, Mark Davis wrote 537 Medicare Part D claims for 132 patients. 92% of them were for generic drugs. CMS names the drug for 353 of them, across 13 drugs with 11 or more claims each, at $2,840 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Mark Davis for performance year 2024, reported through an alternative payment model (APM). Mark Davis accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 984 general payments to Mark Davis from 49 drug and device companies from 2024 to 2025. Speaker and faculty fees make up the largest share, 65% of the total. GlaxoSmithKline, LLC. paid the most, $114,534.